The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of CP-461 in Patients With Advanced Renal Cell Cancer
Official Title: Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer
Study ID: NCT00036036
Brief Summary: The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UCLA Medical Center, Los Angeles, California, United States